← All trials
NCT03837184
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 15, 2019
- Primary completion
- Mar 23, 2021
- Completion date
- Mar 23, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 6
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- AveXis, Inc.Lead sponsor
- Pharmaceutical Research Associates, Inc. (PRA)Collaborator
- AveXis, Inc.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.